BR0316969A - Tratamento de mal de huntington com epa - Google Patents

Tratamento de mal de huntington com epa

Info

Publication number
BR0316969A
BR0316969A BR0316969-3A BR0316969A BR0316969A BR 0316969 A BR0316969 A BR 0316969A BR 0316969 A BR0316969 A BR 0316969A BR 0316969 A BR0316969 A BR 0316969A
Authority
BR
Brazil
Prior art keywords
huntington
epa
disease treatment
disease
treatment
Prior art date
Application number
BR0316969-3A
Other languages
English (en)
Inventor
David Frederick Horrobin
Original Assignee
Amarin Neuroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Neuroscience Ltd filed Critical Amarin Neuroscience Ltd
Publication of BR0316969A publication Critical patent/BR0316969A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

"TRATAMENTO DE MAL DE HUNTINGTON COM EPA". A presente invenção refere-se a uma análise do gene huntington que provê um processo para identificação de pacientes prováveis de responderem a tratamento de mal de Huntignton com ácido eicosapentaenóico, EPA.
BR0316969-3A 2002-12-02 2003-11-26 Tratamento de mal de huntington com epa BR0316969A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228079.0A GB0228079D0 (en) 2002-12-02 2002-12-02 Huntington's Disease
PCT/GB2003/005131 WO2004050913A1 (en) 2002-12-02 2003-11-26 Treatment of huntington’s disease with epa

Publications (1)

Publication Number Publication Date
BR0316969A true BR0316969A (pt) 2005-10-25

Family

ID=9948921

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316969-3A BR0316969A (pt) 2002-12-02 2003-11-26 Tratamento de mal de huntington com epa

Country Status (29)

Country Link
US (2) US20070148643A1 (pt)
EP (1) EP1567667B1 (pt)
JP (1) JP2006507833A (pt)
KR (1) KR20050086895A (pt)
CN (1) CN1717497A (pt)
AT (1) ATE411399T1 (pt)
AU (1) AU2003285519A1 (pt)
BR (1) BR0316969A (pt)
CA (1) CA2506727A1 (pt)
CY (1) CY1108730T1 (pt)
DE (1) DE60324180D1 (pt)
DK (1) DK1567667T3 (pt)
ES (1) ES2315543T3 (pt)
GB (1) GB0228079D0 (pt)
HK (1) HK1081598A1 (pt)
HR (1) HRP20050493A2 (pt)
IS (1) IS7842A (pt)
MX (1) MXPA05005908A (pt)
MY (1) MY138759A (pt)
NO (1) NO20052955L (pt)
NZ (1) NZ539989A (pt)
PL (1) PL376101A1 (pt)
PT (1) PT1567667E (pt)
RU (1) RU2332209C2 (pt)
SI (1) SI1567667T1 (pt)
TW (1) TWI306120B (pt)
UA (1) UA86582C2 (pt)
WO (1) WO2004050913A1 (pt)
ZA (1) ZA200504003B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005208832A1 (en) * 2004-01-19 2005-08-11 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
AU2007282224B2 (en) 2006-08-11 2013-08-29 Vico Therapeutics B.V. Methods and means for treating DNA repeat instability associated genetic disorders
AU2008273094B2 (en) 2007-07-12 2013-05-09 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
WO2009008727A2 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs or tissues
AU2008317566B2 (en) 2007-10-26 2014-05-01 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
NZ587178A (en) 2008-02-08 2011-11-25 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US20110236476A1 (en) 2008-09-02 2011-09-29 Amarin Corporation Plc. Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
KR20140007973A (ko) 2009-02-10 2014-01-20 아마린 파마, 인크. 고중성지방혈증 치료 방법
US20120046342A1 (en) 2009-04-24 2012-02-23 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
NZ627238A (en) 2009-04-29 2016-02-26 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition comprising ethyl eicosapentaenoate
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MY172372A (en) 2009-06-15 2019-11-21 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides
WO2011038122A1 (en) 2009-09-23 2011-03-31 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
EP2516647B1 (en) 2009-12-24 2016-12-14 BioMarin Technologies B.V. Molecule for treating an inflammatory disorder
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
BR112014018427B1 (pt) 2012-01-27 2021-11-03 Biomarin Technologies B.V. Oligonucleotídeos moduladores de rna com características melhoradas para o tratamento da distrofia muscular de duchenne e becker
EP2866801A4 (en) 2012-06-29 2016-02-10 Amarin Pharmaceuticals Ie Ltd METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT SUBJECTED TO STATIN TREATMENT
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR102296068B1 (ko) 2018-09-24 2021-09-02 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116280A1 (en) * 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
CA2216057A1 (en) * 1997-09-19 1999-03-19 Ridha Joober Polymorphic cag repeat-containing gene, diagnosis of psychiatric diseases and therapeutic uses thereof
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
WO2001024781A2 (en) * 1999-10-07 2001-04-12 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulating same

Also Published As

Publication number Publication date
US20090270504A1 (en) 2009-10-29
HRP20050493A2 (en) 2005-10-31
MXPA05005908A (es) 2005-12-12
UA86582C2 (ru) 2009-05-12
HK1081598A1 (en) 2006-05-19
EP1567667B1 (en) 2008-10-15
PT1567667E (pt) 2008-11-04
TWI306120B (en) 2009-02-11
RU2332209C2 (ru) 2008-08-27
CY1108730T1 (el) 2014-04-09
IS7842A (is) 2005-05-12
NO20052955L (no) 2005-06-16
US20070148643A1 (en) 2007-06-28
EP1567667A1 (en) 2005-08-31
KR20050086895A (ko) 2005-08-30
SI1567667T1 (sl) 2009-04-30
CN1717497A (zh) 2006-01-04
ATE411399T1 (de) 2008-10-15
GB0228079D0 (en) 2003-01-08
JP2006507833A (ja) 2006-03-09
DE60324180D1 (de) 2008-11-27
MY138759A (en) 2009-07-31
NZ539989A (en) 2006-11-30
ZA200504003B (en) 2007-01-31
TW200418993A (en) 2004-10-01
RU2005115536A (ru) 2006-01-27
AU2003285519A1 (en) 2004-06-23
PL376101A1 (en) 2005-12-12
ES2315543T3 (es) 2009-04-01
CA2506727A1 (en) 2004-06-17
DK1567667T3 (da) 2009-01-12
WO2004050913A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
BR0316969A (pt) Tratamento de mal de huntington com epa
RS51213B (sr) Farmaceutski vaginalni gel koji sadrži tenofovir
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
BR0311126A (pt) Composições e método para tratar infecção em gado bovino e em suìnos
WO2002082904A3 (en) Method of treating or retarding the development of blindness
UA81676C2 (ru) Композиция для лечения инфекций у крупного рогатого скота и свиней
FR2847262B1 (fr) Bacterie capable de produire de la l-lysine ou de la l-arginine et procede de production de l-lysine ou de l-arginine l'utilisant
ATE531813T1 (de) System zur überwachung einer bakteriellen tumorbehandlung
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
ATE478688T1 (de) Verbindungen für den transfer von oligonukleotiden
PT1267915E (pt) Metodos para tratar doencas com proteina c activada
DE60234250D1 (de) Vorrichtung zur Zell- bzw. Gewebezüchtung
SE0300959D0 (sv) Methods for predicting therapeutic response to agents acting on the growth hormone receptor
SE0402507D0 (sv) Medicinsk lösning, förfarande för framställning och användning därav
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
EA200000740A1 (ru) Способ лечения заболевания хронической закупорки легочных путей
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
WO2003107545A3 (en) TECHNIQUES FOR IDENTIFYING COMPOUNDS FOR TREATING PATHOLOGICAL CONDITIONS
ITBO20030261A1 (it) Unita'di irraggiamento luminoso per diagnosi e cura di problemi cutanei.
DE60313208D1 (de) Phenyl-piperidin-4-yliden-methyl-benzamidderivate zur behandlung von schmerz oder magen-darm-erkrankungen
IL189597A0 (en) Methods of using il-21
FR2845285B1 (fr) Procede d'obtention d'un principe actif de stimulation du bronzage et principe actif obtenu
EA200701920A1 (ru) Использование фенилацетильных производных для производства лекарственных средств для лечения болезни фон хиппеля-линдау (vhl)
ATE297745T1 (de) Chemische modifizierung von harn von säugern

Legal Events

Date Code Title Description
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COMPLEMENTAR 3A ANUIDADE REFERENTE A GUIA 920600966811 E COMPROVAR O RECOLHIMENTO DA 8A ANUIDADE.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2162 DE 12/06/2012.